Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9553087 | 0.93 | TAAR1 (0.50) | TAAR1HTR2ACYP2A6IDO1KDM4E | |
| SCHEMBL9860834 | 0.85 | GFER (0.42) | TAAR1HTR2ACYP2A6KDM4EALDH1A1 | |
| SCHEMBL7961204 | 0.84 | TAAR1 (0.52) | TAAR1HTR2ACYP2A6IDO1 | |
| SCHEMBL626076 | 0.82 | TAAR1 (0.68) | TAAR1HTR2ACYP2A6IDO1ALDH1A1 | |
| SCHEMBL28594032 | 0.80 | TAAR1 (0.48) | TAAR1HTR2AKDM4EALDH1A1 | |
| SCHEMBL9552832 | 0.77 | TAAR1 (0.45) | TAAR1HTR2AALDH1A1 | |
| SCHEMBL926010 | 0.77 | — | — | |
| SCHEMBL9552844 | 0.77 | MAOB (0.46) | TAAR1 | |
| SCHEMBL7904900 | 0.77 | TAAR1 (0.62) | TAAR1HTR2ACYP2A6IDO1 | |
| SCHEMBL9192375 | 0.77 | CA2 (0.42) | TAAR1HTR2ACYP2A6KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| EP-4257593-A1 | CHIRAL MULTIDENTATE LIGAND AND USE THEREOF IN ASYMMETRIC HYDROGENATION | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023064218-A1 | TYRO3 INHIBITORS | Halia Therapeutics, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |
| CN-110914248-A | LXR modulators containing amines or (thio) amides | 菲尼克斯-FXR股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-2850084-B1 | PYRAZOLE COMPOUNDS AS SGLT1 INHIBITORS | LILLY CO ELI (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-3016946-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015003166-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2015-01-08 | — | — | WO | disclosed |
| EP-2702059-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012146659-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2012-11-01 | — | — | WO | disclosed |
| US-20040030189-A1 | Compounds having fungicidal activity and processes to make and use same | RASMUSSEN KLITTICH CARLA JEAN (US) | 2004-02-12 | — | — | US | disclosed |
| EP-1343761-A1 | PIPERIDINE MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | Schering Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1341534-A2 | COMPOUNDS HAVING FUNGICIDAL ACTIVITY AND PROCESSES TO MAKE AND USE SAME | Dow AgroSciences LLC (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6472394-B1 | MCH antagonists and their use in the treatment of obesity | SCHERING CORPORATION | 2002-10-29 | — | — | US | disclosed |
| WO-2002051809-A1 | PIPERIDINE MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002040431-A2 | COMPOUNDS HAVING FUNGICIDAL ACTIVITY AND PROCESSES TO MAKE AND USE SAME | DOW AGROSCIENCES LLC (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-0266662-B1 | PROCESS FOR THE PREPARATION OF POLY(ARYLENSULPHIDES) WITH LOWER CRYSTALLIZATION TEMPERATURE | BAYER AG (DE) | 1992-06-10 | — | — | EP | disclosed |
| EP-0336240-A2 | Poly(arylene sulphides) with lowered temperature of crystallization and process for preparing them | BAYER AG (DE) | 1989-10-11 | — | — | EP | disclosed |
| US-4824933-A | DIMENSIONAL STABILITY, CHEMICAL RESISTANT | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-25 | — | — | US | disclosed |
| EP-0266662-A2 | Process for the preparation of poly(arylensulphides) with lower crystallization temperature | BAYER AG (DE) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030189-A1 | Compounds having fungicidal activity and processes to make and use same | CYP51A1, DDT, CYP4X1 | TAAR1 4228/4885HTR2A 4788/4885CYP2A6 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.